Transition begins Phase 1 study of TT-301

Transition Therapeutics (TSX:TTH; NASDAQ:TTHI) has dosed the first patient with its TT-301 drug candidate in a Phase 1 clinical study. TT-301 has demonstrated efficacy in preclinical models of rheumatoid arthritis, intra cerebral haemorrhage (ICH) and traumatic brain injury (TBI). The Company said data from the trial are a first step in the development of TT-301 [...]

Cormark ups Transition price target 52%

Cormark Securities raised its target price on “buy-rated” Transition Therapeutics (TSX:TTH; NASDAQ:TTHI) to $8 from $5.25, saying it believes Irish partner Elan is likely to move Transition’s ELND005 drug forward into a Phase 3 clinical trial in Alzheimer’s disease.  The stock closed at $3.50 on the TSX Friday. An imbalance of deaths in an ongoing [...]

Transition buys rights to a series of preclinical diabetes assets from Lilly

Transition Therapeutics (TSX:TTH; NASDAQ:TTHI) has expanded its existing relationship with Eli Lilly (NYSE: LLY) by acquiring rights to a series of preclinical diabetes compounds from Lilly under a new licensing and collaboration agreement. Under the accord, Transition will pay Lilly $1 million (U.S.) and Lilly will retain an option to reacquire rights to the compounds [...]

Transition posts positive Phase 2 diabetes results

Transition Therapeutics (TSX:TTH; NASDAQ:TTHI) has reported positive results with type 2 diabetic patients in a Phase 2 clinical study of its gastrin analogue, TT-223 drug. Patients who received the highest daily dose of TT-223 for 12 weeks and completed the entire study without adjusting their diabetes therapies had a “statistically significant” reduction in HbA1c of [...]